Timing and Duration of Acute Hepatitis C Treatment
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
Spontaneous resolution of acute hepatitis C infection cannot be predicted and the majority of
cases persist and become chronic. This randomized trial assesses the efficacy and safety of
peginterferon alfa-2b. The investigators hypothesize that therapy strategies could prevent
the development of chronic hepatitis.
Phase:
Phase 4
Details
Lead Sponsor:
Ain Shams University
Collaborators:
Alexander von Humboldt Association Beth Israel Deaconess Medical Center Fulbright International Society for Infectious Diseases National Institute of Allergy and Infectious Diseases (NIAID) TEMPUS Tempus Labs University Hospital Freiburg